Growth hormone-releasing peptide ghrelin inhibits homocysteine-induced endothelial dysfunction in porcine coronary arteries and human endothelial cells

Journal of Vascular Surgery

Volumn 49, Issue 1, 2009, Pages 199-207

  Hedayati, Nasim ^a   Annambhotla, Suman ^a   Jiang, Jun ^a   Wang, Xinwen ^a   Chai, Hong ^a   Lin, Peter H ^a   Yao, Qizhi ^a   Chen, Changyi ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; BRADYKININ; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GHRELIN; HOMOCYSTEINE; LUCIGENIN; NITROPRUSSIDE SODIUM; SUPEROXIDE;

ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; CHEMOLUMINESCENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MYOGRAPHY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; STAINING; SWINE; VASCULAR TISSUE; VASODILATATION; VASOMOTOR REFLEX; WESTERN BLOTTING;

ANIMALS; CELLS, CULTURED; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GHRELIN; HOMOCYSTEINE; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; RNA, MESSENGER; SUPEROXIDES; SWINE; TISSUE CULTURE TECHNIQUES; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 58749089263     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2008.08.065     Document Type: Article

References (43)

1. Shimizu Y., Nagaya N., Teranishi Y., Imazu M., Yamamoto H., Shokawa T., et al. Ghrelin improves endothelial dysfunction through growth hormone-independent mechanisms in rats. Biochem Biophys Res Commun 310 (2003) 830-835
2. Wren A.M., Small C.J., Abbott C.R., Dhillo W.S., Seal L.J., Cohen M.A., et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes 50 (2001) 2540-2547
3. Nagaya N., Kojima M., Uematsu M., Yamagishi M., Hosoda H., Oya H., et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 280 (2001) R1483-R1487
4. Welch G.N., and Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 338 (1998) 1042-1050
5. Iantorno M., Chen H., Kim J.A., Tesauro M., Lauro D., and Cardillo C. Ghrelin has novel vascular actions that mimic PI 3-kinase-dependent actions of insulin to stimulate production of NO from endothelial cells. Am J Physiol Endocrinol Metab 292 (2007) E756-E764
6. Li W.G., Gavrila D., Liu X., Wang L., Gunnlaugsson S., Stoll L.L., et al. Ghrelin inhibits proinflammatory responses and nuclear factor-κB activation in human endothelial cells. Circulation 109 (2004) 2221-2226
7. Kojima M., Hosoda H., DateY N.M., Matsuo H., and Kangawa K. Ghrelin is a growth-hormone releasing acylated peptide from stomach. Nature 402 (1999) 656-660
8. Cardiovascular Diseases. Heart Disease and Stroke Statistics-2005 Update, American Heart Association. http://www.americanheart.org Accessed: Apr 22, 2008
9. Ross R. Atherosclerosis-An inflammatory disease. N Eng J Med 340 (1999) 115-126
10. Chen C., Conklin B.S., Ren Z., and Zhong D. Homocysteine decreases endothelium-dependent vasorelaxation in porcine arteries. J Surg Res 102 (2002) 22-30
11. Zhou W., Chai H., Lin P.H., Lumsden A.B., Yao Q., and Chen C. Ginsenoside Rb1 blocks homocysteine-induced endothelial dysfunction in porcine coronary arteries. J Vasc Surg 41 (2005) 861-868
12. Nagaya N., Moriya J., Yasumara Y., Uematsu M., Ono F., Shimizu W., et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110 (2004) 3674-3679
13. Nygård O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., and Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337 (1997) 230-236
14. Viani I., Vottero A., Tassi F., Cremonini G., Sartori C., Bernasconi S., et al. Ghrelin inhibits steroid biosynthesis by cultured granulosa-lutein cells. J Clin Endocrinol Metab 93 (2008) 1476-1481
15. Nagaya N., Uematsu M., Kojima M., Ikeda Y., Yoshihara F., Shimizu W., et al. Chronic administration of ghrelin improves left ventricular function and attenuates development of cardiac cachexia in rats with heart failure. Circulation 104 (2001) 1430-1435
16. Burke G.L., Bertoni A.G., Shea S., Tracy R., Watson K.E., Blumenthal R.S., et al. The impact of obesity on cardiovascular disease risk factors and subclinical vascular disease: the Multi-Ethnic Study of Atherosclerosis. Arch Intern Med 168 (2008) 928-935
17. Tesauro M., Schinzari F., Iantorno M., Rizza S., Melina D., Lauro D., et al. Ghrelin endothelial function in patients with metabolic syndrome. Circulation 112 (2005) 2986-2992
18. Smith R.G., Jiang H., and Sun Y. Developments in ghrelin biology and potential clinical relevance. Trends Endocrinol Metab 16 (2005) 436-442
19. Enomoto M., Nagaya N., Uematsu M., Okumura H., Nakagawa E., Ono F., et al. Cardiovascular and hormonal effects of subcutaneous administration of ghrelin, a novel growth hormone-releasing peptide, in healthy humans. Clin Sci 105 (2003) 431-435
20. Nagaya N., and Kangawa K. Ghrelin improves left ventricular dysfunction and cardiac cachexia in heart failure. Curr Opin Pharmacol 3 (2003) 146-151
21. Cummings D.E., Weigle D.S., Frayo R.S., Breen P.A., Ma M.K., Dellinger E.P., et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346 (2002) 1623-1630
22. An J.Y., Choi M.G., Noh J.H., Sohn T.S., Jin D.K., and Kim S. Clinical significance of ghrelin concentration of plasma and tumor tissue in patients with gastric cancer. J Surg Res 143 (2007) 344-349
23. Dixit V.D., Schaffer E.M., Pyle R.S., Collins G.D., Sakthivel S.K., Palaniappan R., et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 114 (2004) 57-66
24. Chen J., Liu X., Shu Q., Li S., and Luo F. Ghrelin attenuates lipopolysaccharide-induced acute lung injury through no pathway. Med Sci Monit 14 (2008) BR141-BR146
25. Surowiec S.M., Conklin B.S., Li L.S., Lin P.H., Lumsden A.B., and Chen C. A new perfusion culture system used to study human vein. J Surg Res 88 (2000) 34-41
26. Kougias P., Chai H., Lin P.H., Lumsden A.B., Yao Q., and Chen C. Adipocyte-derived cytokine resistin causes endothelial dysfunction of porcine coronary arteries. J Vasc Surg 41 (2005) 691-698
27. Paladugu R., Fu W., Conklin B.S., Lin P.H., Lumsden A.B., Yao Q., et al. HIV Tat protein causes endothelial dysfunction in porcine coronary arteries. J Vasc Surg 38; (2003) 549-555
28. Chai H., Zhou Lin P.H., Lumsden A.B., Yao Q., and Chen C. Ginsenosides block HIV protease inhibitor ritonavir-induced vascular dysfunction of porcine coronary arteries. Am J Physiol Heart Circ Physiol 288 (2005) H2965-H2971
29. Groves P., Kurz S., Just H., and Drexler H. Role of endogenous bradykinin in human coronary vasomotor control. Circulation 92 (1995) 3424-3430
30. Leeson C.P., Hingorani A.D., Mullen M.J., Jeerooburkhan K.N.M., and Cole T.J. Glu298Asp endothelial nitric oxide synthase gene polymorphism interacts with environmental and dietary factors to influence endothelial function. Circ Res 90 (2002) 1153-1158
31. Beckman J.S., and Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite the good, the bad, and ugly. Am J Physiol 271 (1996) C1424-C1437
32. Shibanuma M., Kuroki T., and Nose K. Superoxide as a signal for increase in intracellular pH. J Cell Physiol 136 (1988) 379-383
33. 2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells AP-1 as secondary antioxidant-responsive factor. Embo J 12 (1993) 2005-2015
34. Kawczynska-Drozdz A., Olszanecki R., Jawien J., Brzozowski T., Pawlik W.W., Korbut R., and Guzik T.J. Ghrelin inhibits vascular superoxide production in spontaneously hypertensive rats. Am J Hypertens 19 (2006) 764-767
35. Bauersachs J., and Schafer A. Tetrahydrobiopterin and eNOS dimer/monomer ratio-a clue to eNOS uncoupling in diabetes?. Cardiovas Res 65 (2005) 768-769
36. Stuehr D., Pou S., and Rosen G.M. Oxygen reduction by nitric-oxide synthases. J Biol Chem 276 (2001) 14533-14536
37. Topal G., Brunet A., Millanvoye E., Boucher J., Rendu F., Devynck M., et al. Homocysteine induces oxidative stress by uncoupling of no synthase activity through reduction of tetrahydrobiopterin. Free Radic Biol Med 36 (2004) 1532-1541
38. Nagaya N., and Kangawa K. Ghrelin, a novel growth hormone-releasing peptide, in the treatment of chronic heart failure. Regul Pept 114 (2003) 71-77
39. Ohashi R., Yan S., Mu H., Chai H., Yao Q., Lin P.H., et al. Effects of homocysteine and ginsenoside Rb1 on endothelial proliferation and superoxide anion production. J Surg Res 133 (2006) 89-94
40. Wang X., Mu H., Chai H., Liao D., Yao Q., and Chen C. Human immunodeficiency virus protease inhibitor ritonavir inhibits cholesterol efflux from human macrophage-derived foam cells. Am J Pathol 171 (2007) 304-314
41. Xu X., Jhun B.S., Ha C.H., and Jin Z.G. Molecular mechanisms of ghrelin-mediated endothelial nitric oxide synthase activation. Endocrinology 149 (2008) 4183-4192
42. Bhargava S., Parakh R., Manocha A., Ali A., and Srivastava L.M. Prevalence of hyperhomocysteinemia in vascular disease: comparative study of thrombotic venous disease vis-à-vis occlusive arterial disease. Vascular 15 (2007) 149-153
43. Katugampola S.D., Maguire J.J., Kuc R.E., Wiley K.E., and Davenport A.P. Discovery of recently adopted orphan receptors for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system. Can J Physiol Pharmacol 80 (2002) 369-374